Tag: Can-C

Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants

The authors present strong evidence that mitochondrial complex I defects are the major source of oxidative stress in TM cells of patients with POAG. Antioxidants such as Vit E and NAC are likely candidates to reduce ROS production and as complementary agents in the treatment of glaucoma.

The role of free radical-induced lipid oxidation in the development of cataracts in human and canine eyes

Free radical-induced lipid oxidation causes accumulation of lenticular lipid peroxidation (LPO) products. Lens opacity correlates with the level of the LPO accumulation. Oxidation of lens proteins is due to a decreased glutathione concentration in the lens. 

Treatment with 1% N-acetylcarnosine (NAC) protects telomeres to prevent and dissolve mature cataracts in dogs.

Cataracts in small animals are caused by oxidative stress on lens epithelial cells. Treatment with 1% N-acetylcarnosine (NAC) releases L-carnosine ophthalmically, stabilizing telomeres to help prevent and dissolve mature cataracts in dogs.

Oxidative stress in the human trabecular meshwork clinically correlated with primary open-angle glaucoma

Study evaluated intensity of oxidative molecular damage and its clinical correlation to intraocular pressure. It found that oxidative stress could induce human trabecular meshwork degeneration, favoring an increase in IOP, leading to Glaucoma…

Clinical impact of inflammation in dry eye disease

We now have a clearer understanding of the inflammatory processes involved in DED, and there is hope that the still emerging preclinical/clinical findings will be translated into new and highly effective therapies for patients in the near future.

Study finds that Dry Eye Disease (DED) progression may be delayed by breaking the chronic cycle of ocular surface inflammation

The purpose of this article is to review the evidence for the hypothesis that the core mechanism of Dry Eye Disease (DED) is inflammation, including evidence from recent basic, clinical and translational research involving human patients, animal models, and cell cultures.

Dry eye characterized to have clinically-evident inflammation

Dry Eye type II is has been defined to be characterized by clinically-evident inflammation, and clear evidence of epithelial alterations. Type III Dry Eye is a chronic form with accompanied by clinically-evident and chronic inflammation.

In study 90.0% of the eyes treated with N-acetylcarnosine, 1% sol (NAC) showed a gradual improvement in b/c VA to 7-100%

Statistical analysis revealed the significant differences over 6 and 24 months in cumulative positive changes of overall characteristics of cataracts in the NAC-treated Group II from the control Group I.

In clinical test NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared to control at 4-months

1% N-acetylcarnosine (NAC) eye drops were applied topically to the eyes of older drivers. Study results provide a substantial basis for further evaluation of NAC in the treatment and prevention of vision impairment …

Animal Clinical Trials Prove Can-C™ Safe and Effective “A new phenomenon of “melting snow” in only a few short weeks…

The testing of various anti-glycation agents over nearly a decade led a Russian research team to the development of n-alpha-acetylcarnosine as a delivery system for the natural eye anti-oxidant of L-carnosine.

Nac-C Plus™ enhances Can-C™ eye drops to support vision health & repair

Nac-C Plus™ is the only supplement on the market that still uses the original formula invented & tested by Dr Mark Babizhayev to provide optimal support for his Can-C™ eye drops.